 |
|
Notice to Readers: Recommendation From the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2-10 Years at Increased Risk for Invasive Meningococcal Disease
JAMA. 2008;299(5):514-515.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
MMWR. 2007;56:1265-1266
On October 17, 2007, the Food and Drug Administration approved quadrivalent meningococcal conjugate vaccine (MCV4) (Menactra®, Sanofi Pasteur, Swiftwater, Pennsylvania) for use in children aged 2-10 years, in addition to its prior approval for use in persons aged 11-55 years.1 Previous Advisory Committee on Immunization Practices (ACIP) recommendations called for routine vaccination with meningococcal polysaccharide vaccine (MPSV4) (Menomune®, Sanofi Pasteur) of children aged 2-10 years who are at increased risk for meningococcal disease. These children include travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic, children who have terminal complement component deficiencies, and children who have anatomic or functional asplenia.2 This notice provides updated recommendations for meningococcal vaccination among children aged 2-10 years at increased risk for meningococcal disease.
In anticipation of possible licensure of MCV4 for children aged 2-10 years, during February 2007–October 2007, the ACIP meningococcal vaccine workgroup reviewed data on . . . [Full Text of this Article]
|
